These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11642016)

  • 1. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].
    Pédeboscq S; Dubau B; Frappier S; Hernandez V; Veyssières D; Winnock S; Pometan JP
    Pathol Biol (Paris); 2001 Sep; 49(7):540-7. PubMed ID: 11642016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
    Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2001 Aug; 48(2):259-67. PubMed ID: 11481298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
    Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
    Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
    Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A combined dosage form of piperacillin and tazobactam--tazocin].
    Iakovlev SV
    Antibiot Khimioter; 1997; 42(2):5-16. PubMed ID: 9124994
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
    Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics].
    Iwai N; Nakamura H; Miyazu M
    Jpn J Antibiot; 1998 May; 51(5):346-61. PubMed ID: 9693967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
    Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of piperacillin-tazobactam on clinical capillary zone electrophoresis of serum proteins.
    Bossuyt X; Peetermans WE
    Clin Chem; 2002 Jan; 48(1):204-5. PubMed ID: 11751563
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F; Kinzig M
    Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.